Trials / Completed
CompletedNCT05745207
A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants
A First-In-Human, Two-Part Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the safety and tolerability of E2086 following administration of a single oral doses in healthy adult and elderly participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E2086 | E2086 tablets. |
| DRUG | Placebo | E2086 matched placebo tablets. |
Timeline
- Start date
- 2023-02-20
- Primary completion
- 2024-01-18
- Completion
- 2024-01-18
- First posted
- 2023-02-27
- Last updated
- 2024-10-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05745207. Inclusion in this directory is not an endorsement.